Greg Anglin

1.6k total citations
21 papers, 1.2k citations indexed

About

Greg Anglin is a scholar working on Endocrinology, Diabetes and Metabolism, Psychiatry and Mental health and Economics and Econometrics. According to data from OpenAlex, Greg Anglin has authored 21 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Endocrinology, Diabetes and Metabolism, 6 papers in Psychiatry and Mental health and 4 papers in Economics and Econometrics. Recurrent topics in Greg Anglin's work include Sexual function and dysfunction studies (5 papers), Hormonal and reproductive studies (5 papers) and Diabetes Treatment and Management (5 papers). Greg Anglin is often cited by papers focused on Sexual function and dysfunction studies (5 papers), Hormonal and reproductive studies (5 papers) and Diabetes Treatment and Management (5 papers). Greg Anglin collaborates with scholars based in United States, Canada and United Kingdom. Greg Anglin's co-authors include Gerald Brock, Steve Whitaker, Timothy M. Costigan, Chris G. McMahon, V. Watkins, Wei Shen, Jeffrey T. Emmick, Iñigo Sáenz de Tejada, James Knight and Lucio Varanese and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Neurology and Diabetes Care.

In The Last Decade

Greg Anglin

19 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Greg Anglin United States	12	811	689	284	215	193	21	1.2k
Ernst Ulbrich Germany	13	652 0.8×	471 0.7×	189 0.7×	347 1.6×	108 0.6×	24	824
Jay M. Young United States	16	836 1.0×	697 1.0×	167 0.6×	712 3.3×	86 0.4×	22	1.3k
Mike Kirby United Kingdom	16	507 0.6×	530 0.8×	112 0.4×	446 2.1×	34 0.2×	55	1.1k
Fisseha Tesfaye United States	11	663 0.8×	162 0.2×	375 1.3×	321 1.5×	88 0.5×	22	787
Richard Sachse Germany	15	207 0.3×	228 0.3×	62 0.2×	182 0.8×	51 0.3×	34	863
H. Sperling Germany	17	272 0.3×	275 0.4×	59 0.2×	153 0.7×	35 0.2×	81	1.2k
Yiming Yuan China	16	326 0.4×	139 0.2×	142 0.5×	146 0.7×	27 0.1×	69	794
Yanli Zhao China	14	228 0.3×	141 0.2×	130 0.5×	40 0.2×	68 0.4×	54	660
Yuanshan Cui China	21	176 0.2×	313 0.5×	35 0.1×	445 2.1×	25 0.1×	116	1.3k
Henry Schmitt United States	9	122 0.2×	321 0.5×	55 0.2×	19 0.1×	34 0.2×	12	801

Countries citing papers authored by Greg Anglin

Since Specialization

Citations

This map shows the geographic impact of Greg Anglin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Greg Anglin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Greg Anglin more than expected).

Fields of papers citing papers by Greg Anglin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Greg Anglin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Greg Anglin. The network helps show where Greg Anglin may publish in the future.

Co-authorship network of co-authors of Greg Anglin

This figure shows the co-authorship network connecting the top 25 collaborators of Greg Anglin. A scholar is included among the top collaborators of Greg Anglin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Greg Anglin. Greg Anglin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Mullins, Garrett R., Paul Ardayfio, Ivelina Gueorguieva, et al.. (2025). Donanemab immunogenicity in participants with early symptomatic Alzheimer's disease. Alzheimer s & Dementia Translational Research & Clinical Interventions. 11(3). e70149–e70149.

2.

Mullins, Garrett R., Michael E. Hodsdon, Greg Anglin, et al.. (2023). Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies. The Journal of Clinical Endocrinology & Metabolism. 109(2). 361–369. 4 indexed citations

3.

Anglin, Greg, et al.. (2022). 742-P: Antidrug Antibodies Do Not Impact Pharmacokinetics, Efficacy, and Safety of Tirzepatide: Analysis of Data from 7 Phase 3 Studies. Diabetes. 71(Supplement_1). 2 indexed citations

4.

Martinez, James M., Nada Hindiyeh, Greg Anglin, et al.. (2020). Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine. Cephalalgia. 40(9). 978–989. 9 indexed citations

5.

Nilsson, Mary, Brenda Crowe, Greg Anglin, et al.. (2020). Clinical Trial Drug Safety Assessment for Studies and Submissions Impacted by COVID-19. Statistics in Biopharmaceutical Research. 12(4). 498–505. 2 indexed citations

6.

Martinez, James M., Nada Hindiyeh, Greg Anglin, et al.. (2019). Immunogenicity Assessment from Phase 3 Galcanezumab Trials in Patients with Episodic or Chronic Migraine (P1.10-017). Neurology. 92(15_supplement). 2 indexed citations

7.

Frossard, Jean‐Louis, et al.. (2017). Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide. Diabetes Care. 40(5). 647–654. 25 indexed citations

8.

Fairchild, Angelyn, Shelby D. Reed, F. Reed Johnson, et al.. (2017). What is clearance worth? Patients’ stated risk tolerance for psoriasis treatments. Journal of Dermatological Treatment. 28(8). 709–715. 15 indexed citations

9.

Wolka, Anne M., Angelyn Fairchild, Shelby D. Reed, et al.. (2017). Effective Partnering in Conducting Benefit-Risk Patient Preference Studies: Perspectives From a Patient Advocacy Organization, a Pharmaceutical Company, and Academic Stated-Preference Researchers. Therapeutic Innovation & Regulatory Science. 52(4). 507–513. 6 indexed citations

10.

Wolka, Anne M., et al.. (2016). Implementation of Structured Benefit-Risk Assessments in Marketing Authorization Applications: Lessons Learned. Therapeutic Innovation & Regulatory Science. 50(6). 718–723. 6 indexed citations

11.

Miličević, Zvonko, Greg Anglin, Kristine D. Harper, et al.. (2016). Low Incidence of Anti-Drug Antibodies in Type 2 Diabetes Patients Treated with Once Weekly GLP-1 Receptor Agonist Dulaglutide: Incidence of anti-drug antibodies with dulaglutide. 1 indexed citations

12.

Miličević, Zvonko, Greg Anglin, Kristine D. Harper, et al.. (2016). Low incidence of anti‐drug antibodies in patients with type 2 diabetes treated with once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide. Diabetes Obesity and Metabolism. 18(5). 533–536. 22 indexed citations

13.

Tuttle, Katherine R., T. D. McKinney, Jaime A. Davidson, et al.. (2016). Effects of once‐weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials. Diabetes Obesity and Metabolism. 19(3). 436–441. 54 indexed citations

14.

Anglin, Greg, et al.. (2006). Genomic Imprinting in Turner Syndrome: Effects on Response to Growth Hormone and on Risk of Sensorineural Hearing Loss. The Journal of Clinical Endocrinology & Metabolism. 91(8). 3002–3010. 47 indexed citations

15.

Porst, Hartmut, Harin Padma-Nathan, François Giuliano, et al.. (2003). Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. Urology. 62(1). 121–125. 236 indexed citations

16.

Brock, Gerald, Chris G. McMahon, Timothy M. Costigan, et al.. (2002). Efficacy and Safety of Tadalafil for the Treatment of Erectile Dysfunction: Results of Integrated Analyses. The Journal of Urology. 1332–1336. 48 indexed citations

17.

Brock, Gerald, Chris G. McMahon, Timothy M. Costigan, et al.. (2002). Efficacy and Safety of Tadalafil for the Treatment of Erectile Dysfunction: Results of Integrated Analyses. The Journal of Urology. 168(4 Part 1). 1332–1336. 422 indexed citations

18.

Tejada, Iñigo Sáenz de, Greg Anglin, James Knight, & Jeffrey T. Emmick. (2002). Effects of Tadalafil on Erectile Dysfunction in Men With Diabetes. Diabetes Care. 25(12). 2159–2164. 182 indexed citations

19.

Shepherd, Frances A., Raymond P. Abratt, Lucio Crinò, et al.. (2000). The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer. Lung Cancer. 30(2). 117–125. 41 indexed citations

20.

Anderson, Hana, et al.. (1997). Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer.. PubMed. 24(2 Suppl 7). S7–50. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact